Publications and communications of Leslie Correia Da Cruz

E Silva, B.* , Daubry, A.* , Faville, C.* , De Voeght, A., Foguenne, J., Jassin, M., Kwan, O., Correia Da Cruz, L., Carriglio, G., Charles, S., Baron, F., Caers, J., Gothot, A., & Ehx, G. (2026). Biases introduced by Ficoll-based isolation in acute myeloid leukemia sample analyses support the use of hemolysis. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/342923. doi:10.64898/2026.02.11.705243
* These authors have contributed equally to this work.

E Silva, B.* , Daubry, A.* , Faville, C.* , De Voeght, A., Foguenne, J., Jassin, M., Kwan, O., Correia Da Cruz, L., Carriglio, G., Charles, S., Baron, F., Caers, J., Gothot, A., & Ehx, G. (2026). Biases introduced by Ficoll-based isolation in acute myeloid leukemia sample analyses support the use of hemolysis. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/341505.
* These authors have contributed equally to this work.

Faville, C., E Silva, B., Daubry, A., Correia Da Cruz, L., Carriglio, G., Charles, S., De Voeght, A., Fleron, M., Baiwir, D., Mazzucchelli, G., Fillet, M., Willems, L., Baron, F., & Ehx, G. (January 2026). Characterization of Immunogenic MHC-I epitopes presentation in acute myeloid leukemia drug-tolerant persisters [Paper presentation]. Televie Seminar 2026.

Faville, C., E Silva, B., Daubry, A., Correia Da Cruz, L., Carriglio, G., Charles, S., Baiwir, D., Fleron, M., Mazzucchelli, G., De Voeght, A., Willems, L., Fillet, M., Baron, F., & Ehx, G. (November 2025). Characterization of Immunogenic MHC-I epitopes presentation in acute myeloid leukemia drug-tolerant persisters [Poster presentation]. BIS congress.

Correia Da Cruz, L. (September 2025). Exploring Innovative Methods to Uncover Immune Checkpoint Targets in AML [Poster presentation]. GIGA DAY, Liège, Belgium.

Correia Da Cruz, L., Lee, Y., Paik, J. Y., Park, J., Diederich, M.* , & Cerella, C.*. (August 2025). Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients. Biomedicine and Pharmacotherapy, 189, 118287. doi:10.1016/j.biopha.2025.118287
* These authors have contributed equally to this work.

Correia Da Cruz, L., Diederich, M., & Cerella, C. (03 July 2024). Immunophenotype profiling classifies AML patient susceptibility to immunotherapies [Poster presentation]. ISCaM, International Society of Cancer Metabolism, Bruxelles, Belgium.

Correia Da Cruz, L. (06 February 2024). Immunophenotype profiling classifies AML patient susceptibility to immunotherapies [Poster presentation]. Televie Seminar, Bruxelles, Belgium.